Metabolic dysfunction-associated steatohepatitis is jointly driven by hepatic fat accumulation, lipotoxicity, insulin resistance, inflammation, and fibrosis. Targeting lipid metabolism, nuclear receptors, incretin pathways, and FGF signaling has become a major direction in drug development.
Hepatic fibrosis (HF) is a pathological process characterized by excessive deposition and abnormal remodeling of extracellular matrix (ECM) after chronic liver injury. Repeated hepatocyte injury, inflammatory infiltration, cholestasis, lipotoxicity, or immune responses can activate hepatic ...
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.